A number of major Chinese pharmaceutical companies have entered into partnerships and joint ventures with multinational firms to reach global customers, while foreign drugmakers, in turn, gain access to China's domestic markets. Among the collaborations is a 2012 joint venture between Zhejiang Hisun Pharmaceutical and Pfizer, which will aid Hisun's plan to transition from manufacturing APIs to producing branded generics. Simcere Pharmaceutical Group has partnered with Merck and Bristol-Myers Squibb.

Related Summaries